SCHEMBL9901303

SCHEMBL9901303

CONC(=O)C(O)C(Cc1ccccc1)NC(=O)c1cccnc1-n1cc2ccccc2n1

nearest known ligand 0.66

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CAPN1 P07384 20/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15401375 0.92 CAPN1 (0.65) CAPN1
SCHEMBL9900801 0.90 CAPN1 (0.64) CAPN1
SCHEMBL9901102 0.90 CAPN1 (0.54) CAPN1
SCHEMBL9900859 0.90 CAPN1 (0.54) CAPN1
SCHEMBL9900572 0.89 CAPN1 (0.69) CAPN1
SCHEMBL9901539 0.88 CAPN1 (0.52) CAPN1
SCHEMBL9901777 0.88 CAPN1 (0.66) CAPN1
SCHEMBL9900875 0.86 CAPN1 (0.61) CAPN1
SCHEMBL1989478 0.85 CAPN1 (0.54) CAPN1
SCHEMBL9900906 0.84 CAPN1 (0.79) CAPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2648731-B1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V ABBVIE DEUTSCHLAND (DE) 2017-01-25 EP disclosed
US-9062027-B2 Carboxamide compounds and their use as calpain inhibitors V AbbVie Deutschland GmbH & Co. KG (DE) 2015-06-23 US disclosed
US-20140005227-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V AbbVie Deutschland GmbH & Co. KG (DE) 2014-01-02 US disclosed
EP-2648731-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V Abbvie Deutschland GmbH & Co. KG (DE) 2013-10-16 EP disclosed
WO-2012076639-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V ABBOTT GMBH & CO. KG (DE) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140005227-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V CAPN2, CAPN1, CAPN9 CAPN1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.